Richard Klausner | |
|---|---|
 | |
| 11th Director of the National Cancer Institute | |
| In office August 1, 1995 –September 30, 2001 | |
| President | Bill Clinton George W. Bush |
| Preceded by | Samuel Broder |
| Succeeded by | Andrew C. von Eschenbach |
| Personal details | |
| Children | 4 |
| Alma mater | |
| Scientific career | |
| Institutions | |
Richard D. Klausner is an American scientist who served as the 11th director of the National Cancer Institute of the United States.
Klausner was born in 1950or1951. [1] His father was a chemist, and Klausner would visit his father's laboratory as a child. He began studying physics at Yale University, but changed his focus to biology, with the plan of becoming a doctor in a rural area. [1] Klausner received his MD from Duke Medical School in 1976. [2]
In 1979, Klausner joined the National Institutes of Health (NIH) as a postdoctoral fellow. At age 30, Klausner was appointed to the chief of the cell biology and metabolism branch of the National Institute of Child Health and Human Development. [1]
In 1992, he directed the review of the NIH's intramural research programs, in which he recommended sweeping changes. [1] He served as the director of the National Cancer Institute from 1995 to 2001, where he managed a staff of 5,000 employees and a budget of $4.5 billion. [3] In total, he spent more than 20 years at the NIH. [4]
He left the NCI to become the founding director of the Case Institute of Health, Science and Technology of the Case Foundation. [4] [5]
He was the managing partner of the biotech venture capital firm, the Column Group. [6] From 2002 to 2005, he was the executive director of the Bill & Melinda Gates Foundation. [3] [7]
He was a member of the Searle Scholars advisory board. [8] He was a scientific advisor at the Fred Hutchinson Cancer Research Center. [9] He has been an Advisor to the Presidents of the Academies for counter-terrorism and a liaison to the White House Office of Science & Technology Policy, [6] and was the chief strategy advisor for USAID. [10]
Klausner co-founded Juno Therapeutics in 2013, GRAIL in 2015. [11] [12] and MindStrong Health in 2014. He was the chief medical officer of Illumina from 2013 to 2016. [13]
In 2022, Klausner co-founded Altos Labs and is currently Chief Scientist and Board Co-Chairman of the company. [14]
He was president of the American Society for Clinical Investigation from 1995 to 1996. [12]
His research focused on T cells and the potential for CAR-T therapies. [15] He also has published research on the genetics of Von Hippel–Lindau disease, a condition which predisposes a person to developing cancer. [9] He is an author of more than 300 scientific articles. [6]
Klausner has two sons and twin daughters. [1]
Harold Eliot Varmus is an American Nobel Prize-winning scientist. He is currently the Lewis Thomas University Professor of Medicine at Weill Cornell Medicine and a senior associate at the New York Genome Center.
The National Cancer Institute (NCI) coordinates the United States National Cancer Program and is part of the National Institutes of Health (NIH), which is one of eleven agencies that are part of the U.S. Department of Health and Human Services. The NCI conducts and supports research, training, health information dissemination, and other activities related to the causes, prevention, diagnosis, and treatment of cancer; the supportive care of cancer patients and their families; and cancer survivorship.
Vincent Theodore DeVita Jr. is the Amy and Joseph Perella Professor of Medicine at Yale Cancer Center, and a Professor of Epidemiology and Public Health. He directed the Yale Cancer Center from 1993 to 2003. He has been president of the board of directors of the American Cancer Society (2012-2013). He is internationally recognized as a pioneer in the field of oncology for his work on combination-chemotherapy treatments.
Elias Zerhouni is an Algerian-born American scientist, radiologist and biomedical engineer.
Sue Desmond-Hellmann is an American oncologist and biotechnology leader who served as the Chief Executive Officer of the Bill & Melinda Gates Foundation from 2014 to 2020. In March 2024 she was elected as a board member of OpenAI. She was previously Chancellor of the University of California, San Francisco (UCSF), the first woman to hold the position, and Arthur and Toni Rembe Rock Distinguished Professor, and before that president of product development at Genentech, where she played a role in the development of the first gene-targeted cancer drugs, Avastin and Herceptin.
Joe G. N. "Skip" Garcia is an American pulmonary scientist, physician and academician.
John E. Niederhuber was the 13th director of the National Cancer Institute (NCI), from 2006 until July, 2010, succeeding Andrew von Eschenbach, who went on to become a director at biotechnology firm BioTime. A nationally renowned surgeon and researcher, Dr. Niederhuber has dedicated his four-decade career to the treatment and study of cancer - as a professor, cancer center director, National Cancer Advisory Board chair, external advisor to the NCI, grant reviewer, and laboratory investigator supported by NCI and the National Institutes of Health. He is now Executive Vice President/CEO Inova Translational Medicine Institute and Inova Health System and co-director, Johns Hopkins Clinical Research Network.
Charles L. Sawyers is a Howard Hughes Medical Institute (HHMI) investigator who holds the Marie-Josée and Henry R. Kravis Chair of the Human Oncology and Pathogenesis Program (HOPP) at Memorial Sloan Kettering Cancer Center (MSK). HOPP is a program created in 2006 that comprises researchers from many disciplines to bridge clinical and laboratory discoveries.
Larry Kwak is an American cancer researcher who works at City of Hope in Duarte, California and is the Director of the Toni Stephenson Lymphoma Center at City of Hope. Dr. Kwak formerly worked at the University of Texas MD Anderson Cancer Center. He was included on Time's list of 2010's most influential people.
William Douglas Figg is an American scientist (pharmacologist). He is a senior investigator (tenured) at the National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland. He holds multiple titles within the NCI: Associate Director of the Center for Cancer Research, Co-Director of the Office of Translational Resources, Acting Branch Chief for the Genitourinary Malignancies Branch, Chief of the Clinical Pharmacology Program, and head of the Molecular Pharmacology Section. Figg is also the Co-chief of Basic Research at the Center for Prostate Disease Research within the Walter Reed National Military Medical Center – Murtha Cancer Center in Bethesda, Maryland.
The Foundation for the National Institutes of Health (FNIH) is a not-for-profit, 501(c)(3) charitable organization established by the US Congress in 1990. Located in North Bethesda, MD, the FNIH raises private-sector funds, and creates and manages alliances with public and private institutions in support of the mission of the National Institutes of Health (NIH).
Douglas R. Lowy is the current Principal Deputy Director of the U.S. National Cancer Institute (NCI) and Chief of the Laboratory of Cellular Oncology within the Center for Cancer Research at NCI. Lowy served as Acting Director of NCI between April 2015 and October 2017 following the resignation of Harold E. Varmus, M.D., and again between April and November 2019, while Director Norman Sharpless served as the Acting Commissioner of the U.S. Food and Drug Administration. He resumed the role of Acting Director on May 1, 2022, when Sharpless stepped down until October 3, 2022 when Monica Bertagnolli was appointed Director. He resumed the role again in November 2023 after Bertagnolli resigned to serve as director of the National Institutes of Health.
William G. Kaelin Jr. is an American Nobel laureate physician-scientist. He is a professor of medicine at Harvard University and the Dana–Farber Cancer Institute. His laboratory studies tumor suppressor proteins. In 2016, Kaelin received the Albert Lasker Award for Basic Medical Research and the AACR Princess Takamatsu Award. He also won the Nobel Prize in Physiology or Medicine in 2019 along with Peter J. Ratcliffe and Gregg L. Semenza.
Bruce Allan Chabner is an American medical researcher who worked at the National Cancer Institute and now is a professor of medicine at Harvard Medical School. He is also the director of clinical research at the Cancer Center at Massachusetts General Hospital. His research focuses on anti-folate drugs for the treatment of cancer. His work at NIH led to the development of Taxol, a commonly prescribed breast cancer drug.
Alan S. Rabson was an American pathologist and cancer researcher, and was deputy director of the National Cancer Institute from 1995 to 2015.
Eliseo J. Pérez-Stable is a Cuban-American physician-scientist. He is the director of the National Institute on Minority Health and Health Disparities.
Worta J. McCaskill-Stevens was an American physician-scientist and medical oncologist specialized in cancer disparities research, management of comorbidities within clinical trials, and molecular research for cancer prevention interventions. She was chief of the community oncology and prevention trials research group at the National Cancer Institute.
W. Kimryn Rathmell is an American physician-scientist whose work focuses on the research and treatment of patients with kidney cancers. She is the Hugh Jackson Morgan Professor and Chair of the Department of Medicine at Vanderbilt University Medical Center (VUMC), and Physician-in-Chief for Vanderbilt University Adult Hospital and Clinics in Nashville, Tennessee. On Nov. 17, 2023, Rathmell was announced as the next Director of the National Cancer Institute.
Margaret Anne Tucker is an American oncologist and physician-scientist specialized in environmental and genetic epidemiology, familial cancers, and melanomas. She is a scientist emeritia at the National Cancer Institute (NCI). Tucker was a commissioned officer in the United States Public Health Service Commissioned Corps and served as director of the NCI human genetics program from 2005 until her retirement in June 2018.
Mitchell H. Gail is an American physician-scientist and biostatistician. He is a distinguished investigator at the National Cancer Institute.
| International | |
|---|---|
| National | |
